Skip to main content
Top
Published in: AIDS Research and Therapy 1/2005

Open Access 01-12-2005 | Research

Scutellaria baicalensis decreases ritonavir-induced nausea

Authors: Han Aung, Sangeeta Mehendale, Wei-Tien Chang, Chong-Zhi Wang, Jing-Tian Xie, Chun-Su Yuan

Published in: AIDS Research and Therapy | Issue 1/2005

Login to get access

Abstract

Background

Protease inhibitors, particularly ritonavir, causes significant gastrointestinal disturbances such as nausea, even at low doses. This ritonavir-induced nausea could be related to its oxidative stress in the gut. Alleviation of drug-induced nausea is important in effectively increasing patients' compliance and improving their quality of life. Conventional anti-emetic drugs can only partially abate the symptoms in these patients, and their cost has also been a concern. Rats respond to nausea-producing emetic stimuli by increasing consumption of non-nutritive substances like kaolin or clay, a phenomenon known as pica. In this study, we used this rat pica model to evaluate the effects of Scutellaria baicalensis, a commonly used oriental herbal medicine, on ritonavir-induced nausea.

Results

Rats treated with 20 mg/kg ritonavir significant caused increases of kaolin consumption at 24 to 48 hr (P < 0.01). Pretreatment with 0.3 and 3 mg/kg Scutellaria baicalensis extract significantly decreased ritonavir-induced kaolin intake in a dose-related manner (P < 0.01). Compared to vehicle treatment, the extract completely prevented ritonavir-induced kaolin consumption at dose 3 mg/kg. The area under the curves (AUC) for kaolin intake from time 0 to 120 hr for vehicle only, ritonavir only, SbE 0.3 mg/kg plus ritonavir, and SbE 3 mg/kg plus ritonavir were 27.3 g•hr, 146.7 g•hr, 123.2 g•hr, and 32.7 g•hr, respectively. The reduction in area under the curves of kaolin intake from time 0 to 120 hr between ritonavir only and SbE 0.3 mg/kg plus ritonavir, ritonavir only and SbE 3 mg/kg plus ritonavir were 16.0% and 77.7%, respectively.

Conclusion

Scutellaria baicalensis significantly attenuated ritonavir-induced pica, and demonstrated a potential in treating ritonavir-induced nausea.
Appendix
Available only for authorised users
Literature
1.
go back to reference Sande MA, Volberding PA: The Medical Management of AIDS. 1999, Philadelphia, W.B. Saunders & Co., 6th. Sande MA, Volberding PA: The Medical Management of AIDS. 1999, Philadelphia, W.B. Saunders & Co., 6th.
2.
go back to reference Proctor VE, Tesfa A, Tompkins DC: Barriers to adherence to highly active antiretroviral therapy as expressed by people living with HIV/AIDS. AIDS Patient Care STDS. 1999, 13: 535-544.CrossRefPubMed Proctor VE, Tesfa A, Tompkins DC: Barriers to adherence to highly active antiretroviral therapy as expressed by people living with HIV/AIDS. AIDS Patient Care STDS. 1999, 13: 535-544.CrossRefPubMed
3.
go back to reference Bartlett JA: Addressing the challenges of adherence. J Acquir Immune Defic Syndr. 2002, 29 Suppl 1: S2-10.CrossRefPubMed Bartlett JA: Addressing the challenges of adherence. J Acquir Immune Defic Syndr. 2002, 29 Suppl 1: S2-10.CrossRefPubMed
4.
go back to reference Carr A: Improvement of the study, analysis, and reporting of adverse events associated with antiretroviral therapy. Lancet. 2002, 360: 81-85. 10.1016/S0140-6736(02)09341-8CrossRefPubMed Carr A: Improvement of the study, analysis, and reporting of adverse events associated with antiretroviral therapy. Lancet. 2002, 360: 81-85. 10.1016/S0140-6736(02)09341-8CrossRefPubMed
5.
go back to reference Hamilton JD, Hartigan PM, Simberkoff MS, Day PL, Diamond GR, Dickinson GM, Drusano GL, Egorin MJ, George WL, Gordin FM: A controlled trial of early versus late treatment with zidovudine in symptomatic human immunodeficiency virus infection. Results of the Veterans Affairs Cooperative Study. N Engl J Med. 1992, 326: 437-443.CrossRefPubMed Hamilton JD, Hartigan PM, Simberkoff MS, Day PL, Diamond GR, Dickinson GM, Drusano GL, Egorin MJ, George WL, Gordin FM: A controlled trial of early versus late treatment with zidovudine in symptomatic human immunodeficiency virus infection. Results of the Veterans Affairs Cooperative Study. N Engl J Med. 1992, 326: 437-443.CrossRefPubMed
6.
go back to reference Spruance SL, Pavia AT, Mellors JW, Murphy R, Gathe JJ, Stool E, Jemsek JG, Dellamonica P, Cross A, Dunkle L: Clinical efficacy of monotherapy with stavudine compared with zidovudine in HIV-infected, zidovudine-experienced patients. A randomized, double-blind, controlled trial. Bristol-Myers Squibb Stavudine/019 Study Group. Ann Intern Med. 1997, 126: 355-363.CrossRefPubMed Spruance SL, Pavia AT, Mellors JW, Murphy R, Gathe JJ, Stool E, Jemsek JG, Dellamonica P, Cross A, Dunkle L: Clinical efficacy of monotherapy with stavudine compared with zidovudine in HIV-infected, zidovudine-experienced patients. A randomized, double-blind, controlled trial. Bristol-Myers Squibb Stavudine/019 Study Group. Ann Intern Med. 1997, 126: 355-363.CrossRefPubMed
7.
go back to reference Lichterfeld M, Nischalke HD, Bergmann F, Wiesel W, Rieke A, Theisen A, Fatkenheuer G, Oette M, Carls H, Fenske S, Nadler M, Knechten H, Wasmuth JC, Rockstroh JK: Long-term efficacy and safety of ritonavir/indinavir at 400/400 mg twice a day in combination with two nucleoside reverse transcriptase inhibitors as first line antiretroviral therapy. HIV Med. 2002, 3: 37-43. 10.1046/j.1464-2662.2001.00091.xCrossRefPubMed Lichterfeld M, Nischalke HD, Bergmann F, Wiesel W, Rieke A, Theisen A, Fatkenheuer G, Oette M, Carls H, Fenske S, Nadler M, Knechten H, Wasmuth JC, Rockstroh JK: Long-term efficacy and safety of ritonavir/indinavir at 400/400 mg twice a day in combination with two nucleoside reverse transcriptase inhibitors as first line antiretroviral therapy. HIV Med. 2002, 3: 37-43. 10.1046/j.1464-2662.2001.00091.xCrossRefPubMed
8.
go back to reference Lalezari JP, DeJesus E, Northfelt DW, Richmond G, Wolfe P, Haubrich R, Henry D, Powderly W, Becker S, Thompson M, Valentine F, Wright D, Carlson M, Riddler S, Haas FF, DeMasi R, Sista PR, Salgo M, Delehanty J: A controlled Phase II trial assessing three doses of enfuvirtide (T-20) in combination with abacavir, amprenavir, ritonavir and efavirenz in non-nucleoside reverse transcriptase inhibitor-naive HIV-infected adults. Antivir Ther. 2003, 8: 279-287.PubMed Lalezari JP, DeJesus E, Northfelt DW, Richmond G, Wolfe P, Haubrich R, Henry D, Powderly W, Becker S, Thompson M, Valentine F, Wright D, Carlson M, Riddler S, Haas FF, DeMasi R, Sista PR, Salgo M, Delehanty J: A controlled Phase II trial assessing three doses of enfuvirtide (T-20) in combination with abacavir, amprenavir, ritonavir and efavirenz in non-nucleoside reverse transcriptase inhibitor-naive HIV-infected adults. Antivir Ther. 2003, 8: 279-287.PubMed
9.
go back to reference Gartland M: AVANTI 3: a randomized, double-blind trial to compare the efficacy and safety of lamivudine plus zidovudine versus lamivudine plus zidovudine plus nelfinavir in HIV-1-infected antiretroviral-naive patients. Antivir Ther. 2001, 6: 127-134.PubMed Gartland M: AVANTI 3: a randomized, double-blind trial to compare the efficacy and safety of lamivudine plus zidovudine versus lamivudine plus zidovudine plus nelfinavir in HIV-1-infected antiretroviral-naive patients. Antivir Ther. 2001, 6: 127-134.PubMed
10.
go back to reference Gelmon K, Montaner JS, Fanning M, Smith JR, Falutz J, Tsoukas C, Gill J, Wells G, O'Shaughnessy M, Wainberg M: Nature, time course and dose dependence of zidovudine-related side effects: results from the Multicenter Canadian Azidothymidine Trial. Aids. 1989, 3: 555-561.CrossRefPubMed Gelmon K, Montaner JS, Fanning M, Smith JR, Falutz J, Tsoukas C, Gill J, Wells G, O'Shaughnessy M, Wainberg M: Nature, time course and dose dependence of zidovudine-related side effects: results from the Multicenter Canadian Azidothymidine Trial. Aids. 1989, 3: 555-561.CrossRefPubMed
11.
go back to reference Elperin A, Sax P: A patient's guide to protease inhibitors. AIDS Clin Care. 1996, 8: 83-84.PubMed Elperin A, Sax P: A patient's guide to protease inhibitors. AIDS Clin Care. 1996, 8: 83-84.PubMed
12.
go back to reference Mangum EM, Graham KK: Lopinavir-Ritonavir: a new protease inhibitor. Pharmacotherapy. 2001, 21: 1352-1363. 10.1592/phco.21.17.1352.34419CrossRefPubMed Mangum EM, Graham KK: Lopinavir-Ritonavir: a new protease inhibitor. Pharmacotherapy. 2001, 21: 1352-1363. 10.1592/phco.21.17.1352.34419CrossRefPubMed
13.
go back to reference Greenblatt DJ, von Moltke LL, Harmatz JS, Fogelman SM, Chen G, Graf JA, Mertzanis P, Byron S, Culm KE, Granda BW, Daily JP, Shader RI: Short-term exposure to low-dose ritonavir impairs clearance and enhances adverse effects of trazodone. J Clin Pharmacol. 2003, 43: 414-422. 10.1177/0091270003251864CrossRefPubMed Greenblatt DJ, von Moltke LL, Harmatz JS, Fogelman SM, Chen G, Graf JA, Mertzanis P, Byron S, Culm KE, Granda BW, Daily JP, Shader RI: Short-term exposure to low-dose ritonavir impairs clearance and enhances adverse effects of trazodone. J Clin Pharmacol. 2003, 43: 414-422. 10.1177/0091270003251864CrossRefPubMed
14.
go back to reference Nadler JP, Gathe JC, Pollard RB, Richmond GJ, Liao Q, Griffith S, Tracey Lancaster C, Hernandez JE, Pappa KA: Twice-daily amprenavir 1200 mg versus amprenavir 600 mg/ritonavir 100 mg, in combination with at least 2 other antiretroviral drugs, in HIV-1-infected patients. BMC Infect Dis. 2003, 3: 10- 10.1186/1471-2334-3-10PubMedCentralCrossRefPubMed Nadler JP, Gathe JC, Pollard RB, Richmond GJ, Liao Q, Griffith S, Tracey Lancaster C, Hernandez JE, Pappa KA: Twice-daily amprenavir 1200 mg versus amprenavir 600 mg/ritonavir 100 mg, in combination with at least 2 other antiretroviral drugs, in HIV-1-infected patients. BMC Infect Dis. 2003, 3: 10- 10.1186/1471-2334-3-10PubMedCentralCrossRefPubMed
15.
go back to reference Barlett JG: HIV:Current diagnosis, management, and treatment options. HIV Disease Management Guide. 2004, 101-122. , PDR. Barlett JG: HIV:Current diagnosis, management, and treatment options. HIV Disease Management Guide. 2004, 101-122. , PDR.
16.
go back to reference Meyer M: Palliative care and AIDS: 2--Gastrointestinal symptoms. Int J STD AIDS. 1999, 10: 495-505; quiz 506-7. 10.1258/0956462991914573CrossRefPubMed Meyer M: Palliative care and AIDS: 2--Gastrointestinal symptoms. Int J STD AIDS. 1999, 10: 495-505; quiz 506-7. 10.1258/0956462991914573CrossRefPubMed
17.
go back to reference Mitchell D, Wells C, Hoch N, Lind K, Woods SC, Mitchell LK: Poison induced pica in rats. Physiol Behav. 1976, 17: 691-697. 10.1016/0031-9384(76)90171-2CrossRefPubMed Mitchell D, Wells C, Hoch N, Lind K, Woods SC, Mitchell LK: Poison induced pica in rats. Physiol Behav. 1976, 17: 691-697. 10.1016/0031-9384(76)90171-2CrossRefPubMed
18.
go back to reference Takeda N, Hasegawa S, Morita M, Matsunaga T: Pica in rats is analogous to emesis: an animal model in emesis research. Pharmacol Biochem Behav. 1993, 45: 817-821. 10.1016/0091-3057(93)90126-ECrossRefPubMed Takeda N, Hasegawa S, Morita M, Matsunaga T: Pica in rats is analogous to emesis: an animal model in emesis research. Pharmacol Biochem Behav. 1993, 45: 817-821. 10.1016/0091-3057(93)90126-ECrossRefPubMed
19.
go back to reference Takeda N, Hasegawa S, Morita M, Horii A, Uno A, Yamatodani A, Matsunaga T: Neuropharmacological mechanisms of emesis. I. Effects of antiemetic drugs on motion- and apomorphine-induced pica in rats. Methods Find Exp Clin Pharmacol. 1995, 17: 589-590.PubMed Takeda N, Hasegawa S, Morita M, Horii A, Uno A, Yamatodani A, Matsunaga T: Neuropharmacological mechanisms of emesis. I. Effects of antiemetic drugs on motion- and apomorphine-induced pica in rats. Methods Find Exp Clin Pharmacol. 1995, 17: 589-590.PubMed
20.
go back to reference Takeda N, Hasegawa S, Morita M, Horii A, Uno A, Yamatodani A, Matsunaga T: Neuropharmacological mechanisms of emesis. II. Effects of antiemetic drugs on cisplatin-induced pica in rats. Methods Find Exp Clin Pharmacol. 1995, 17: 647-652.PubMed Takeda N, Hasegawa S, Morita M, Horii A, Uno A, Yamatodani A, Matsunaga T: Neuropharmacological mechanisms of emesis. II. Effects of antiemetic drugs on cisplatin-induced pica in rats. Methods Find Exp Clin Pharmacol. 1995, 17: 647-652.PubMed
21.
go back to reference Aung HH, Dey L, Mehendale S, Xie JT, Wu JA, Yuan CS: Scutellaria baicalensis extract decreases cisplatin-induced pica in rats. Cancer Chemother Pharmacol. 2003, 52: 453-458. 10.1007/s00280-003-0694-9CrossRefPubMed Aung HH, Dey L, Mehendale S, Xie JT, Wu JA, Yuan CS: Scutellaria baicalensis extract decreases cisplatin-induced pica in rats. Cancer Chemother Pharmacol. 2003, 52: 453-458. 10.1007/s00280-003-0694-9CrossRefPubMed
22.
go back to reference Aung HH, Mehendale SR, Xie JT, Moss J, Yuan CS: Methylnaltrexone prevents morphine-induced kaolin intake in the rat. Life Sci. 2004, 74: 2685-2691. 10.1016/j.lfs.2003.08.047CrossRefPubMed Aung HH, Mehendale SR, Xie JT, Moss J, Yuan CS: Methylnaltrexone prevents morphine-induced kaolin intake in the rat. Life Sci. 2004, 74: 2685-2691. 10.1016/j.lfs.2003.08.047CrossRefPubMed
23.
go back to reference Zhong DS, Lu XH, Conklin BS, Lin PH, Lumsden AB, Yao Q, Chen C: HIV protease inhibitor ritonavir induces cytotoxicity of human endothelial cells. Arterioscler Thromb Vasc Biol. 2002, 22: 1560-1566. 10.1161/01.ATV.0000034707.40046.02CrossRefPubMed Zhong DS, Lu XH, Conklin BS, Lin PH, Lumsden AB, Yao Q, Chen C: HIV protease inhibitor ritonavir induces cytotoxicity of human endothelial cells. Arterioscler Thromb Vasc Biol. 2002, 22: 1560-1566. 10.1161/01.ATV.0000034707.40046.02CrossRefPubMed
24.
go back to reference Conklin BS, Fu W, Lin PH, Lumsden AB, Yao Q, Chen C: HIV protease inhibitor ritonavir decreases endothelium-dependent vasorelaxation and increases superoxide in porcine arteries. Cardiovasc Res. 2004, 63: 168-175. 10.1016/j.cardiores.2004.03.020CrossRefPubMed Conklin BS, Fu W, Lin PH, Lumsden AB, Yao Q, Chen C: HIV protease inhibitor ritonavir decreases endothelium-dependent vasorelaxation and increases superoxide in porcine arteries. Cardiovasc Res. 2004, 63: 168-175. 10.1016/j.cardiores.2004.03.020CrossRefPubMed
25.
go back to reference Shao ZH, Li CQ, Vanden Hoek TL, Becker LB, Schumacker PT, Wu JA, Attele AS, Yuan CS: Extract from Scutellaria baicalensis Georgi attenuates oxidant stress in cardiomyocytes. J Mol Cell Cardiol. 1999, 31(10): 1885-1895. 10.1006/jmcc.1999.1021.CrossRef Shao ZH, Li CQ, Vanden Hoek TL, Becker LB, Schumacker PT, Wu JA, Attele AS, Yuan CS: Extract from Scutellaria baicalensis Georgi attenuates oxidant stress in cardiomyocytes. J Mol Cell Cardiol. 1999, 31(10): 1885-1895. 10.1006/jmcc.1999.1021.CrossRef
26.
go back to reference Denissen JF, Grabowski BA, Johnson MK, Buko AM, Kempf DJ, Thomas SB, Surber BW: Metabolism and disposition of the HIV-1 protease inhibitor ritonavir (ABT-538) in rats, dogs, and humans. Drug Metab Dispos. 1997, 25: 489-501.PubMed Denissen JF, Grabowski BA, Johnson MK, Buko AM, Kempf DJ, Thomas SB, Surber BW: Metabolism and disposition of the HIV-1 protease inhibitor ritonavir (ABT-538) in rats, dogs, and humans. Drug Metab Dispos. 1997, 25: 489-501.PubMed
27.
go back to reference Shibata N, Gao W, Okamoto H, Kishida T, Iwasaki K, Yoshikawa Y, Takada K: Drug interactions between HIV protease inhibitors based on physiologically-based pharmacokinetic model. J Pharm Sci. 2002, 91: 680-689. 10.1002/jps.10051CrossRefPubMed Shibata N, Gao W, Okamoto H, Kishida T, Iwasaki K, Yoshikawa Y, Takada K: Drug interactions between HIV protease inhibitors based on physiologically-based pharmacokinetic model. J Pharm Sci. 2002, 91: 680-689. 10.1002/jps.10051CrossRefPubMed
28.
go back to reference Yamaji H, Matsumura Y, Yoshikawa Y, Takada K: Pharmacokinetic interactions between HIV-protease inhibitors in rats. Biopharm Drug Dispos. 1999, 20: 241-247. 10.1002/(SICI)1099-081X(199907)20:5<241::AID-BDD182>3.0.CO;2-UCrossRefPubMed Yamaji H, Matsumura Y, Yoshikawa Y, Takada K: Pharmacokinetic interactions between HIV-protease inhibitors in rats. Biopharm Drug Dispos. 1999, 20: 241-247. 10.1002/(SICI)1099-081X(199907)20:5<241::AID-BDD182>3.0.CO;2-UCrossRefPubMed
29.
go back to reference Nieuwkerk PT, Sprangers MA, Burger DM, Hoetelmans RM, Hugen PW, Danner SA, van Der Ende ME, Schneider MM, Schrey G, Meenhorst PL, Sprenger HG, Kauffmann RH, Jambroes M, Chesney MA, de Wolf F, Lange JM: Limited patient adherence to highly active antiretroviral therapy for HIV-1 infection in an observational cohort study. Arch Intern Med. 2001, 161: 1962-1968. 10.1001/archinte.161.16.1962CrossRefPubMed Nieuwkerk PT, Sprangers MA, Burger DM, Hoetelmans RM, Hugen PW, Danner SA, van Der Ende ME, Schneider MM, Schrey G, Meenhorst PL, Sprenger HG, Kauffmann RH, Jambroes M, Chesney MA, de Wolf F, Lange JM: Limited patient adherence to highly active antiretroviral therapy for HIV-1 infection in an observational cohort study. Arch Intern Med. 2001, 161: 1962-1968. 10.1001/archinte.161.16.1962CrossRefPubMed
30.
go back to reference Lai S, Lai H, Celentano DD, Vlahov D, Ren S, Margolick J, Lima JA, Bartlett JG: Factors associated with accelerated atherosclerosis in HIV-1-infected persons treated with protease inhibitors. AIDS Patient Care STDS. 2003, 17: 211-219. 10.1089/108729103321655863CrossRefPubMed Lai S, Lai H, Celentano DD, Vlahov D, Ren S, Margolick J, Lima JA, Bartlett JG: Factors associated with accelerated atherosclerosis in HIV-1-infected persons treated with protease inhibitors. AIDS Patient Care STDS. 2003, 17: 211-219. 10.1089/108729103321655863CrossRefPubMed
31.
go back to reference Richman DD, Fischl MA, Grieco MH, Gottlieb MS, Volberding PA, Laskin OL, Leedom JM, Groopman JE, Mildvan D, Hirsch MS: The toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. N Engl J Med. 1987, 317: 192-197.CrossRefPubMed Richman DD, Fischl MA, Grieco MH, Gottlieb MS, Volberding PA, Laskin OL, Leedom JM, Groopman JE, Mildvan D, Hirsch MS: The toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. N Engl J Med. 1987, 317: 192-197.CrossRefPubMed
32.
go back to reference Langtry HD, Campoli-Richards DM: Zidovudine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy. Drugs. 1989, 37: 408-450.CrossRefPubMed Langtry HD, Campoli-Richards DM: Zidovudine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy. Drugs. 1989, 37: 408-450.CrossRefPubMed
33.
go back to reference Han P, Arnold B: The challenge of chronic AIDS-related nausea and vomiting. J Palliat Med. 2001, 4: 65-68. 10.1089/109662101300052040CrossRefPubMed Han P, Arnold B: The challenge of chronic AIDS-related nausea and vomiting. J Palliat Med. 2001, 4: 65-68. 10.1089/109662101300052040CrossRefPubMed
34.
go back to reference Kimura YOHTTAS: Studies on Scutellaria Radix. VI. Effects of flavanone compounds on lipid peroxidation in rat liver. Chem Pharm Bull. 1982, 30: 1792-1795.CrossRefPubMed Kimura YOHTTAS: Studies on Scutellaria Radix. VI. Effects of flavanone compounds on lipid peroxidation in rat liver. Chem Pharm Bull. 1982, 30: 1792-1795.CrossRefPubMed
35.
go back to reference Huang KC: The Pharmacology of Chinese Herbs. 1999, Boca Raton, FL, CRC Press. Huang KC: The Pharmacology of Chinese Herbs. 1999, Boca Raton, FL, CRC Press.
36.
go back to reference Kimuya Y, Kubo M, Tani T, Arichi S, Okuda H: Studies on Scutellariae Radix. IV. Effects on lipid peroxidation in rat liver. Chem Pharm Bull (Tokyo). 1981, 29: 2610-2617.CrossRef Kimuya Y, Kubo M, Tani T, Arichi S, Okuda H: Studies on Scutellariae Radix. IV. Effects on lipid peroxidation in rat liver. Chem Pharm Bull (Tokyo). 1981, 29: 2610-2617.CrossRef
37.
go back to reference Wu JA, Attele AS, Zhang L, Yuan CS: Anti-HIV activity of medicinal herbs: usage and potential development. Am J Chin Med. 2001, 29: 69-81. 10.1142/S0192415X01000083CrossRefPubMed Wu JA, Attele AS, Zhang L, Yuan CS: Anti-HIV activity of medicinal herbs: usage and potential development. Am J Chin Med. 2001, 29: 69-81. 10.1142/S0192415X01000083CrossRefPubMed
38.
go back to reference Gabrielska J, Oszmianski J, Zylka R, Komorowska M: Antioxidant activity of flavones from Scutellaria baicalensis in lecithin liposomes. Z Naturforsch [C]. 1997, 52: 817-823. Gabrielska J, Oszmianski J, Zylka R, Komorowska M: Antioxidant activity of flavones from Scutellaria baicalensis in lecithin liposomes. Z Naturforsch [C]. 1997, 52: 817-823.
39.
go back to reference Gao D, Sakurai K, Chen J, Ogiso T: Protection by baicalein against ascorbic acid-induced lipid peroxidation of rat liver microsomes. Res Commun Mol Pathol Pharmacol. 1995, 90(1): 103-114. Gao D, Sakurai K, Chen J, Ogiso T: Protection by baicalein against ascorbic acid-induced lipid peroxidation of rat liver microsomes. Res Commun Mol Pathol Pharmacol. 1995, 90(1): 103-114.
40.
go back to reference Gao D, Tawa R, Masaki H, Okano Y, Sakurai H: Protective effects of baicalein against cell damage by reactive oxygen species. Chem Pharm Bull (Tokyo). 1998, 46: 1383-1387.CrossRef Gao D, Tawa R, Masaki H, Okano Y, Sakurai H: Protective effects of baicalein against cell damage by reactive oxygen species. Chem Pharm Bull (Tokyo). 1998, 46: 1383-1387.CrossRef
41.
go back to reference Hamada H, Hiramatsu M, Edamatsu R, Mori A: Free radical scavenging action of baicalein. Arch Biochem Biophys. 1993, 306(1): 261-266. 10.1006/abbi.1993.1509.CrossRef Hamada H, Hiramatsu M, Edamatsu R, Mori A: Free radical scavenging action of baicalein. Arch Biochem Biophys. 1993, 306(1): 261-266. 10.1006/abbi.1993.1509.CrossRef
42.
go back to reference Duggan J, Peterson WS, Schutz M, Khuder S, Charkraborty J: Use of complementary and alternative therapies in HIV-infected patients. AIDS Patient Care STDS. 2001, 15: 159-167. 10.1089/108729101750123661CrossRefPubMed Duggan J, Peterson WS, Schutz M, Khuder S, Charkraborty J: Use of complementary and alternative therapies in HIV-infected patients. AIDS Patient Care STDS. 2001, 15: 159-167. 10.1089/108729101750123661CrossRefPubMed
43.
go back to reference Zhan L, Yue ST, Xue YX, Attele AS, Yuan CS: Effects of qian-kun-nin, a Chinese herbal medicine formulation, on HIV positive subjects: a pilot study. Am J Chin Med. 2000, 28: 305-312. 10.1142/S0192415X00000362CrossRefPubMed Zhan L, Yue ST, Xue YX, Attele AS, Yuan CS: Effects of qian-kun-nin, a Chinese herbal medicine formulation, on HIV positive subjects: a pilot study. Am J Chin Med. 2000, 28: 305-312. 10.1142/S0192415X00000362CrossRefPubMed
Metadata
Title
Scutellaria baicalensis decreases ritonavir-induced nausea
Authors
Han Aung
Sangeeta Mehendale
Wei-Tien Chang
Chong-Zhi Wang
Jing-Tian Xie
Chun-Su Yuan
Publication date
01-12-2005
Publisher
BioMed Central
Published in
AIDS Research and Therapy / Issue 1/2005
Electronic ISSN: 1742-6405
DOI
https://doi.org/10.1186/1742-6405-2-12

Other articles of this Issue 1/2005

AIDS Research and Therapy 1/2005 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.